Home/Pipeline/VitoKine™ Platform

VitoKine™ Platform

Solid Tumors

Pre-clinicalActive

Key Facts

Indication

Solid Tumors

Phase

Pre-clinical

Status

Active

Company

Cugene

About Cugene

Cugene is a private, clinical-stage biotech founded in 2018, focusing on precision-engineered immunotherapies for autoimmune diseases and cancer. Its core technology platform involves immuno-engineering to create selective biologics, including engineered cytokines and bispecific antibodies with proprietary masking domains. The lead program, CUG252, is a Treg-selective IL-2 for autoimmune conditions, while its oncology pipeline features TILKine™ and VitoKine™ bispecific platforms designed to transform cold tumors. The company is science-driven, led by an experienced team, and is currently in the pre-clinical to early clinical development stage.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed